Local business? Support local news on VanAlstyne.city

Back to Texas

Texas Secures $7.5 Million Settlement with Tris Pharma Over Pediatric ADHD Drug Marketing

State prosecutors finalized a resolution concluding allegations that the pharmaceutical manufacturer misled Medicaid providers regarding how quickly an ADHD medication acted for pediatric patients.

Jubal Pennington· AI-assisted, edited by Jake Team

October 2, 20261 min read

Pediatric healthcare settlement - illustration, Jake Team LLC

Van Alstyne, Texas — State legal authorities concluded a $7.5 million financial resolution with Tris Pharmaceuticals, resolving allegations that the drugmaker defrauded the Texas Medicaid program by misrepresenting how quickly and effectively an attention-deficit medication worked for children.

The agreement concludes litigation initiated by state prosecutors in 2023 against the pharmaceutical manufacturer and corporate executive Ketan Mehta. State investigators alleged that the company orchestrated a deceptive promotional campaign concerning Dyanavel XR, an attention-deficit/hyperactivity disorder medication marketed for pediatric patients.

According to state enforcement filings, company sales representatives conducted thousands of promotional presentations to medical practitioners, including healthcare professionals enrolled in the state Medicaid network. Regulators asserted that sales representatives made unverified representations claiming the medication took effect far more rapidly than alternative therapies while providing additional clinical advantages that lacked scientific substantiation.

"Tris Pharma is now paying millions of dollars for misleading folks about ADHD drugs being prescribed to children." — Texas Attorney General Ken Paxton

Under the terms of the finalized agreement, the pharmaceutical manufacturer agreed to transfer $7.5 million to the state treasury to resolve the statutory claims, ending the enforcement action without further trial proceedings.

In Van Alstyne along the Grayson and Collin county line, the attorney general's agreement underscores statewide regulatory vigilance over commercial drug promotions.

Sources: Office of the Texas Attorney General (October 2026): https://www.texasattorneygeneral.gov/news/releases/attorney-general-paxton-secures-75-million-settlement-tris-pharma-misrepresenting-efficacy-adhd-drug

Share

Jubal Pennington· AI-assisted, edited by Jake Team

Jubal Pennington writes about community life, schools, public safety, and neighborhood happenings around Van Alstyne.

Related Stories

More in Sport

Sport

Gafford and Martin Filled the Jobs Left Around Dallas’s Stars

Daniel Gafford and Caleb Martin did not need big scoring nights to shape Dallas’ 116-94 victory over Golden State. Their timely baskets, rebounding and defensive contributions gave the Mavericks enough connective play for Cooper Flagg and P.J. Washington to turn a comfortable lead into a rout.

Cody FerrisNovember 19, 20263 min read
Sport

Joakim Soria’s Texas Value Reaches Beyond His 17 Saves

Joakim Soria’s first Hall of Fame ballot appearance brings his Texas years into focus: a modest 2013, an efficient 2014 and a career whose value rests on preventing runs across changing roles.

Cody FerrisNovember 17, 20264 min read